Iranian
Biomedical Journal
Volume 30, Issue 4 (9-2026)
IBJ 2026, 30(4): 212-224 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khatami S, Ghavidel Yazdi S, Forouzanfar F, Bakhshian O, Eghbali P, Saburi E. Translating Mesenchymal Stem Cell Research into Chronic Kidney Disease Therapy: A Systematic and Clinical Review. IBJ 2026; 30 (4) :212-224
URL: http://ibj.pasteur.ac.ir/article-1-5143-en.html
URL: http://ibj.pasteur.ac.ir/article-1-5143-en.html
Somayeh Khatami 
, Somayeh Ghavidel Yazdi , Fatemeh Forouzanfar , Omid Bakhshian , Parnian Eghbali , Ehsan Saburi *
, Somayeh Ghavidel Yazdi , Fatemeh Forouzanfar , Omid Bakhshian , Parnian Eghbali , Ehsan Saburi *
Abstract:
Chronic kidney disease (CKD) is a progressive disorder with high morbimortality and limited treatment options. Mesenchymal stem cells (MSCs) have emerged as a promising therapy because of their immunomodulatory and regenerative properties. This systematic review evaluates the therapeutic potential of MSC therapy for CKD by searching databases PubMed, Medline, Embase, the Cochrane Library, and Scopus from January 2000 to May 2026 using keywords “mesenchymal stem cells,” “cell therapy,” and “renal failure”. Among 1,525 identified studies, 19 met the inclusion criteria, covering preclinical and clinical investigations. Findings indicated contribution of MSC therapy to renal tissue repair, immunomodulation, and functional recovery, with some studies reporting improvements in glomerular filtration rate, reduced proteinuria, and histological recovery of kidney tissue. While the short-term safety profiles were favorable, the long-term efficacy and optimal administration protocols remain uncertain. Further high-quality clinical trials are needed to establish standardized treatment protocols and validate long-term benefits.
Type of Study: Systematic Review |
Subject:
Tissue Engineering and Cell Biology
References
1. El Nahas AM, Bello AK. Chronic kidney disease: The global challenge. Lancet. 2005;365(9456):331-40. [DOI:10.1016/S0140-6736(05)17789-7]
2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease-a systematic review and meta-analysis. Plos One. 2016;11(7):e0158765. [DOI:10.1371/journal.pone.0158765]
3. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: Global dimension and perspectives. Lancet. 2013;382(9888):260-72. [DOI:10.1016/S0140-6736(13)60687-X]
4. Yan H, Xu J, Xu Z, Yang B, Luo P, He Q. Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesis. Biomed Pharmacother. 2021:143:112115. [DOI:10.1016/j.biopha.2021.112115]
5. Yuan Q, Tang B, Zhang C. Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target Ther. 2022;7(1):182. [DOI:10.1038/s41392-022-01036-5]
6. López-Novoa JM, Martínez-Salgado C, Rodríguez-Peña AB, Hernández FJL. Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectives. Pharmacol Ther. 2010;128(1):61-81. [DOI:10.1016/j.pharmthera.2010.05.006]
7. Eirin A, Lerman LO. Mesenchymal stem cell treatment for chronic renal failure. Stem Cell Res Ther. 2014;5(4):83. [DOI:10.1186/scrt472]
8. Papazova DA, Oosterhuis NR, Gremmels H, Van Koppen A, Joles JA, Verhaar MC. Cell-based therapies for experimental chronic kidney disease: A systematic review and meta-analysis. Dis Model Mech. 2015;8(3):281-93. [DOI:10.1242/dmm.017699]
9. Hickson LJ, Eirin A, Lerman LO. Challenges and opportunities for stem cell therapy in patients with chronic kidney disease. Kidney Int. 2016;89(4):767-78. [DOI:10.1016/j.kint.2015.11.023]
10. Raoufinia R, Rahimi HR, Saburi E, Moghbeli M. Advances and challenges of the cell-based therapies among diabetic patients. J Transl Med. 2024 May 8;22(1):435. doi: 10.1186/s12967-024-05226-3. PMID: 38720379; PMCID: PMC11077715. [DOI:10.1186/s12967-024-05226-3]
11. Saburi E, Abazari MF, Hassannia H, Mansour RN, Eshaghi-Gorji R, Gheibi M, et al. The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19. Gene. 2021 Apr 20;777:145471. [DOI:10.1016/j.gene.2021.145471]
12. Rajabi M, Shafaeibajestan S, Asadpour S, Alyari G, Taei N, Kohkalani M, et al. Primary progressive multiple sclerosis: new therapeutic approaches. Neuropsychopharmacol Rep. 2025;45(3):e70039. [DOI:10.1002/npr2.70039]
13. Fleig SV, Humphreys BD. Rationale of mesenchymal stem cell therapy in kidney injury. Nephron Clin Pract. 2014;127(1-4):75-80. [DOI:10.1159/000363680]
14. Pool M, Leuvenink H, Moers C. Reparative and regenerative effects of mesenchymal stromal cells-promising potential for kidney transplantation? Int J Mol Sci. 2019;20(18):4614. [DOI:10.3390/ijms20184614]
15. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, et al. Autologous mesenchymal stromal cells and kidney transplantation: A pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011;6(2):412-22. [DOI:10.2215/CJN.04950610]
16. El‐Ansary M, Saadi G, Abd El‐Hamid SM. Mesenchymal stem cells are a rescue approach for recovery of deteriorating kidney function. Nephrology. 2012;17(7):650-7. [DOI:10.1111/j.1440-1797.2012.01622.x]
17. Reinders ME, De Fijter JW, Roelofs H, Bajema IM, De Vries DK, Schaapherder AF, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: Results of a phase I study. Stem Cells Transl Med. 2013;2(2):107-11. [DOI:10.5966/sctm.2012-0114]
18. Reinders ME, Bank JR, Dreyer GJ, Roelofs H, Heidt S, Roelen DL, et al. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients. J Transl Med. 2014;12(1):1-12. [DOI:10.1186/s12967-014-0331-x]
19. Zhang L, Lai X, Guo Y, Ma J, Fang J, Li G, et al. Autologous bone marrow-derived mesenchymal stem cells for interstitial fibrosis and tubular atrophy: A pilot study. Ren Fail. 2021;43(1):1266-75. [DOI:10.1080/0886022X.2021.1968432]
20. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786-802. [DOI:10.1016/S0140-6736(21)00519-5]
21. Rahyussalim AJ, Saleh I, Kurniawati T, Lutfi APWY. Improvement of renal function after human umbilical cord mesenchymal stem cell treatment on chronic renal failure and thoracic spinal cord entrapment: A case report. J Med Case Rep. 2017;11(1):334. [DOI:10.1186/s13256-017-1489-7]
22. Makhlough A, Shekarchian S, Moghadasali R, Einollahi B, Dastgheib M, Janbabaee G, et al. Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up. Cytotherapy. 2018;20(5):660-9. [DOI:10.1016/j.jcyt.2018.02.368]
23. Li Y, Ricardo SD, Samuel CS. Enhancing the therapeutic potential of mesenchymal stromal cell-based therapies with an anti-fibrotic agent for the treatment of chronic kidney disease. Int J Mol Sci. 2022;23(11):6035. [DOI:10.3390/ijms23116035]
24. Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: A randomized, placebo-controlled, dose escalation study. EBioMedicine. 2016;12:263-9. [DOI:10.1016/j.ebiom.2016.09.011]
25. Shao Z, Meng X, Meng F. Efficacy and safety of mesenchymal stem cell in Chinese patients with chronic renal failure: A pilot study in Shandong province, China. Pak J Pharm Sci. 2021;34(3):1227-31.
26. Park BD, Faubel S. Acute kidney injury and acute respiratory distress syndrome. Crit Care Clin. 2021;37(4):835-49. [DOI:10.1016/j.ccc.2021.05.007]
27. Swaminathan M, Kopyt N, Atta MG, Radhakrishnan J, Umanath K, Nguyen S, et al. Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation. Stem Cells Transl Med. 2021;10(12):1588-601. [DOI:10.1002/sctm.21-0043]
28. Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: A multicenter clinical study. Arthritis Res Ther. 2014;16(2):79. [DOI:10.1186/ar4520]
29. Sabir S, Shahzad M, Malik UI, Satti HS, Iftikhar R, Sial N. Effect of mesenchymal stem cell infusion in stage II-IV diabetic nephropathy. J Coll Physicians Surg Pak. 2026;36(1):31-7. [DOI:10.29271/jcpsp.2026.01.31]
30. Carstens MH, García N, Mandayam S, Workeneh B, Pastora I, Calderón C, et al. Safety of stromal vascular fraction cell therapy for chronic kidney disease of unknown cause (Mesoamerican nephropathy). Stem Cells Transl Med. 2023;12(1):7-16. [DOI:10.1093/stcltm/szac080]
31. Riordan NH, Ambrozic RA, Paz-Rodríguez J. Case report: Effect of umbilical cord mesenchymal stem cells on immunoglobulin A nephropathy after acute renal failure. Am J Transl Res. 2022;14(7):4855-9.
32. Villanueva S, González F, Lorca E, Tapia A, López VG, Strodthoff R, et al. Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility. Kidney Res Clin Pract. 2019;38(2):176-85. [DOI:10.23876/j.krcp.18.0139]
33. Kim JS, Lee JH, Kwon O, Cho JH, Choi JY, Park SH, et al. Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy. Kidney Res Clin Pract. 2017;36(2):200-4. [DOI:10.23876/j.krcp.2017.36.2.200]
34. Stavas J, Silva AL, Wooldridge TD, Aqeel A, Saad T, Prakash R, et al. Rilparencel (Renal Autologous Cell Therapy-REACT®) for chronic kidney disease and type 1 and type 2 diabetes: Phase 2 trial design evaluating bilateral kidney dosing and redosing triggers. Am J Nephrol. 2024;55(3):389-98. [DOI:10.1159/000537942]
35. Stavas J, Thajudeen B, Coca S, Silva A, Butler E, Detwiler R, et al. Renal autologous cell therapy in type 2 diabetes with late stage 4 diabetes-related chronic kidney disease: Trial design and early analysis. Blood Purif. 2023;52(2):114-21. [DOI:10.1159/000527582]
36. Stavas J, Filler G, Jain D, Ludlow J, Basu J, Payne R, et al. Renal autologous cell therapy to stabilize function in diabetes-related chronic kidney disease: Corroboration of mechanistic action with cell marker analysis. Kidney Int Rep. 2022;7(7):1619-29. [DOI:10.1016/j.ekir.2022.04.014]
37. Stavas J, Diaz-Gonzalez de Ferris M, Johns A, Jain D, Bertram T. Protocol and baseline data on renal autologous cell therapy injection in adults with chronic kidney disease secondary to congenital anomalies of the kidney and urinary tract. Blood Purif. 2021;50(4-5):678-83. [DOI:10.1159/000512586]
38. Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP. Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure. Blood Purif. 2003;21(1):64-71. [DOI:10.1159/000067864]
39. Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol. 2008;19(5):1034-40. [DOI:10.1681/ASN.2007080895]
40. Rajabi M, Shafaeibajestan S, Asadpour S, Alyari G, Taei N, Kohkalani M, et al. Primary progressive multiple sclerosis: New therapeutic approaches. Neuropsychopharmacol Rep. 2025;45(3): e70039. [DOI:10.1002/npr2.70039]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |